Scientists at the University of Liverpool have demonstrated that a drug for treating hepatitis B virus (HBV) could be mass-produced for only £24 ($36) per person per year, versus the current UK NHS price of £4,600, and ...
Apr 22, 2015
0
23
(HealthDay)—Doctors should regularly screen people at high risk for contracting the hepatitis B virus, which causes chronic illness and can lead to liver cancer if left untreated, a national panel of health experts has ...
May 27, 2014
0
0
(HealthDay)—Adults at high risk for hepatitis B should be screened for the viral infection, according to a draft recommendation from the U.S. Preventive Services Task Force.
Feb 11, 2014
0
0
A recent discovery by scientists at A*STAR's Singapore Institute for Clinical Sciences (SICS), in close collaboration with researchers at the Singapore Immunology Network (SIgN), provides hope for a new personalised treatment ...
Sep 20, 2013
0
0
Almost 60 children were taken to hospital in eastern India after they were mistakenly instructed to swallow a hepatitis B vaccine instead of polio drops, officials said Monday.
Sep 16, 2013
0
0
(HealthDay)—Vaccination rates among America's children remain high, despite a serious resurgence of measles among unvaccinated children and adults, health officials reported Thursday.
Sep 13, 2013
0
0
"Hepatitis B virus (HBV) infection causes infant fulminant hepatitis (IFH), and chronic HBV infection may progress to chronic liver disease (CLD) and hepatocellular carcinoma (HCC). Taiwan launched a nationwide HBV immunization ...
Sep 3, 2013
0
0
Liver cancer is the sixth most common cancer worldwide and the third most deadly. It mainly affects men over the age of 40, most often with cirrhosis or hepatitis B or C. But in Peru, it also uncharacteristically affects ...
Sep 3, 2013
0
0
Most people react very well to vaccinations and have an adequate immune response against the pathogens. The lack of response to vaccines, so-called vaccine failure, affects between one and ten percent of people. The reasons ...
Aug 15, 2013
0
3
(HealthDay)—Tivicay (dolutegravir) has been approved by the U.S. Food and Drug Administration to treat infection with HIV-1, a strain of the virus that causes AIDS.
Aug 13, 2013
0
0
